HHS Public Access
Author manuscript
Author Manuscript
Mov Disord. Author manuscript; available in PMC 2016 October 01.
Published in final edited form as:
Mov Disord. 2015 October ; 30(12): 1657–1663. doi:10.1002/mds.26291.
Exercise Improves Cognition in Parkinson’s Disease: the PRETPD Randomized Clinical Trial
Fabian J. David, PhD1, Julie A. Robichaud, PT, PhD2, Sue E. Leurgans, PhD3, Cynthia
Poon, PhD1, Wendy M. Kohrt, PhD4, Jennifer G. Goldman, MD, MS5, Cynthia L. Comella,
MD5, David E. Vaillancourt, PhD6, and Daniel M. Corcos, PhD1,5
1Department
Author Manuscript
of Physical Therapy and Human Movement Sciences, Northwestern University,
Chicago, USA
2Department
of Physical Therapy, University of Illinois at Chicago, Chicago, USA
3Departments
of Neurological Sciences and Preventive Medicine, Rush University Medical
Center, Chicago, USA
4Division
of Geriatric Medicine, University of Colorado School of Medicine, Aurora, USA
5Department
of Neurological Sciences, Section of Parkinson Disease and Movement Disorders,
Rush University Medical Center, Chicago, USA
6Departments
of Applied Physiology and Kinesiology, Biomedical Engineering, and Neurology,
University of Florida, Gainesville, USA
Author Manuscript
Abstract
Background—This paper reports on the findings of the effect of two structured exercise
interventions on secondary cognitive outcomes which were gathered as part of the Progressive
Resistance Exercise Training in Parkinson’s disease randomized controlled trial.
Methods—This study was a prospective, parallel-group, single-center trial. Fifty-one nondemented patients with mild-to-moderate Parkinson’s disease were randomly assigned either to
Corresponding author: Fabian J. David, PhD, Department of Physical Therapy and Human Movement Sciences, Northwestern
University, 645 North Michigan Avenue, Suite 1100, Chicago, Illinois 60611, Tel: (919) 414-9839, Fax: (312) 908-0741,
Fabian.J.David@gmail.com.
Clinical Trial Registration: clinicaltrials.gov, NCT00591344.
Author Manuscript
Author Roles: FJD was responsible for acquisition of data, analysis and interpretation of the data, statistical analysis, drafting the
manuscript, and administrative, technical, or material support. JAR was responsible for study concept and design, obtaining funding,
acquisition of data, analysis and interpretation of the data, critical revision of the manuscript for important intellectual content, and
administrative, technical, or material support. CP was responsible for acquisition of data, analysis and interpretation of the data,
critical revision of the manuscript for important intellectual content, and administrative, technical, or material support. SEL
participated in study concept and design, obtaining funding, interpretation of the data, statistical analysis, and critical revision of the
manuscript for important intellectual content. DEV was responsible for study concept and design, obtaining funding, interpretation of
the data, critical revision of the manuscript for important intellectual content, study supervision, and administrative, technical, or
material support. WMK was responsible for study concept and design, obtaining funding, interpretation of the data, critical revision of
the manuscript for important intellectual content, study supervision, and administrative, technical, or material support. CLC was
responsible for study concept and design, interpretation of the data, critical revision of the manuscript for important intellectual
content, study supervision, and administrative, technical, or material support. JGG was responsible for interpretation of the data,
critical revision of the manuscript for important intellectual content, and technical, or material support. DMC was responsible for
study concept and design, obtaining funding, interpretation of the data, critical revision of the manuscript for important intellectual
content, study supervision, and administrative, technical, or material support.
David et al.
Page 2
Author Manuscript
modified Fitness Counts or to Progressive Resistance Exercise, and were followed for 24 months.
Cognitive outcomes were the Digit Span, Stroop, and Brief Test of Attention.
Results—Eighteen patients in modified Fitness Counts and 20 patients in Progressive Resistance
Exercise completed the trial. At 12 and at 24 months no differences between groups were
observed. At 12 months, relative to baseline, modified Fitness Counts improved on the Digit Span
(estimated change, 0.3; Inter-Quartile Range, 0, 0.7; p=0.04) and Stroop (0.3; 0, 0.6; p=0.04), and
Progressive Resistance Exercise improved only on the Digit Span (0.7; 0.3, 1; p<0.01). At 24
months, relative to baseline, modified Fitness Counts improved on the Digit Span (0.7; 0.3, 1.7;
p<0.01) and Stroop (0.3; 0.1, 0.5; p=0.03), while Progressive Resistance Exercise improved on the
Digit Span (0.5; 0.2, 0.8; p<0.01), Stroop (0.2; −0.1, 0.6; p=0.048), and Brief Test of Attention
(0.3; 0, 0.8; p=0.048). No neurologic or cognitive adverse events were seen.
Author Manuscript
Conclusions—This study provides Class IV level of evidence that 24 months of Progressive
Resistance Exercise or modified Fitness Counts may improve attention and working memory in
non-demented patients with mild-to-moderate Parkinson’s disease.
Keywords
Progressive resistance exercise; Parkison’s disease; Randomized controlled trial; Attention;
Memory
INTRODUCTION
Author Manuscript
Cognitive impairment1–4 including attention and working memory deficits5 are frequently
observed in Parkinson disease (PD). It is estimated that 78% of patients with PD will
develop dementia.6 Treating cognitive impairment is a challenge as it is often unresponsive
to dopaminergic therapies.7 Recent work from the 90+ study suggests that poor overall
physical performance is a strong predictor of cognitive decline.8 The beneficial effects of
exercise training on cognitive performance are well recognized in aging,9 as well as in
individuals with dementia.10 In PD, preliminary research on the effects of exercise on
cognition is promising,11 but long-term randomized controlled trials are needed.12
Author Manuscript
Recently, the Progressive Resistance Exercise Training in PD (PRET-PD)13 trial reported,
that compared to modified Fitness Counts (mFC),14 Progressive Resistance Exercise
Training (PRET) reduced the off-medication motor section of the Unified Parkinson’s
Disease Rating Scale (UPDRS-III) at the study end-point of 24 months by 7.3 points. More
recently, we also reported our findings associated with physical function, a secondary
outcome.15 Here, we examine the cognitive domain and report the effect of mFC and PRET
on cognitive outcomes related to attention and working memory. This paper addresses the
following questions at the 12- and at the 24-month time point: relative to baseline, does
exercise improve cognitive function, and is one type of exercise modality better at
improving cognitive function in mild-to-moderate PD? Because of the known benefits of
exercise on cognitive performance,9–11 we hypothesized that exercise would improve
cognitive function in mild-to-moderate PD.
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 3
Author Manuscript
METHODS
Study Design and Participants
Author Manuscript
The PRET-PD trial was a prospective, parallel-group, single-center, randomized controlled
trial between September 2007 and July 2011.13 Patients with idiopathic PD, confirmed by a
Movement Disorders specialist,16 were self-referred or recruited from Rush University
Medical Center. Patients were eligible if they were 50 to 67 years (the Physical Activity
Readiness Questionnaire,17 a screening tool used for exclusion was only validated for use
with persons younger than 69, the maximum age at study completion); on stable
dopaminergic therapy; and able to walk for six minutes. Patients were ineligible if they had
a neurological history other than PD; significant arthritis; failed the Physical Activity
Readiness Questionnaire;17 had a Mini-Mental State Examination score<2318; were already
exercising; or had deep brain stimulation surgery for PD. Patients were followed every 6
months for 24 months or until they withdrew from the study. Each participant provided
written informed consent approved by the local Institutional Review Boards.
Interventions
Author Manuscript
Details of the exercise intervention used in the PRET-PD trial have been published
previously.13 In brief, the mFC was an exercise program recommended by the National
Parkinson Foundation and focused on stretches, balance exercises, breathing, and nonprogressive strengthening (manual chapters two and three).14 PRET was a weight-lifting
program where the load against which the muscle worked was systematically and
progressively increased. The PRET program consisted of strengthening exercises that were
directed at all the major muscle groups.19 The programs were identical in all aspects
(duration of exercise, number of exercise sessions, and time with the personal trainer) except
for the specific exercises. Patients participated in their respective interventions twice a
week19 for 24 months. One-on-one exercise with a certified personal trainer was provided
for both weekly exercise sessions during the first six months; the trainer-assisted sessions
were reduced to once per week after six months. Patients in the mFC and PRET groups were
instructed not to engage in additional exercise.
Study Procedures
Author Manuscript
All cognitive assessments were performed after 12-hour overnight withdrawal of
dopaminergic medication20 by individuals trained in administering standardized cognitive
assessments and blinded to group assignments at the Clinical Motor Control Laboratory at
the University of Illinois at Chicago. Off-medication assessment was completed in the
morning. The cognitive outcomes were one of many outcome domains tested; they were
clinical status, the primary outcome, and bradykinesia and strength, tremor, physical
function15 and gait, quality of life, and cognition, which were secondary outcomes. The
order of testing was pseudo-randomized between outcome domains and between cognitive
outcomes. The off medication testing session lasted for approximately 3 hours. This was
followed by ingestion of anti-Parkinsonian medication, a break for lunch, confirming a
clinical response to the medication, and then repeating the entire testing procedure while on
anti-Parkinsonian medication. In this paper we will report findings related to the cognitive
outcomes only while off medication for the following reasons: first, the effects of antiMov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 4
Author Manuscript
Parkinsonian medication on cognitive outcomes are not well understood;21 second, antiParkinsonian medication could possibly mask the effects of exercise; and third, because onmedication testing was always conducted in the afternoon following off-medication testing
in the morning, fatigue was a potential confound with respect to cognitive performance.
Cognitive Outcomes
The cognitive outcomes were: the Digit Span Forwards and Backwards to assess working
memory,22 which had a sum score that ranged from 0–30; the Stroop Color-Word
Interference to measure selective attention and conflict resolution,23 which had a T-score, a
standardized normative metric, with a mean of 50 and a standard deviation of 10; and the
Brief Test of Attention to assess selective attention,24 which had a sum score that ranged
from 0–20.
Author Manuscript
Follow-up
Patients in the mFC and PRET groups returned to the laboratory at 6, 12, 18, and 24 months
for follow-up. The entire baseline assessment procedure was repeated at each follow-up
visit.
Randomization and Blinding
Author Manuscript
The statistician matched the enrolled patients in pairs by sex and off-medication UPDRS-III
scores,25 and randomly assigned one member of each pair to PRET and the other member to
mFC using a random-length permuted block design.26 Randomization resulted in a parallel
group design with a 1:1 allocation ratio. Patients started exercising within a month of
randomization. Research personnel involved in data collection were blinded to group
assignment. The patients knew their treatment assignment but were unaware of the study
hypothesis and were explicitly instructed not to discuss their exercise program with the
raters.
Statistical Analysis
Author Manuscript
All raw scores were converted to z-scores. For the Digit Span22 and the Stroop23 published
norms were used to calculate z-scores. For the Brief Test of Attention, the pooled baseline
mean and standard deviation was used to calculate z-scores. To reduce Type I errors, we
used only the 12 and 24 month change from baseline z-scores. The distributional
assumptions for parametric testing were not met; therefore non-parametric methods were
used. The Wilcoxon rank-sum test was used to analyze the differences between the mFC and
PRET groups at 12 and 24 months. The Wilcoxon signed-rank test was used to analyze
change from baseline at 12 and 24 months. We also calculated correlations of changes in
cognitive outcomes with changes in clinical and functional outcomes published previously.
In addition, a sensitivity analysis using the last available observation carried forward
(LOCF) was performed to evaluate the impact of missing data. Since these outcomes were
not used to power the original randomized controlled trial, we did not adjust the significance
level for multiple outcomes. All statistical tests were 2-tailed, with P value<0.05 for
statistical significance.
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 5
Author Manuscript
RESULTS
Of the 51 patients enrolled, 46 patients (mFC, n=23; PRET, n=23) completed the 12-month
follow-up and 38 patients (mFC, n=18; PRET, n=20) completed the 24-month follow-up. At
baseline, the mFC and PRET groups did not differ on demographic, clinical, and cognitive
outcomes (Table 1).
Difference between mFC and PRET groups at 12 and 24 months
There were no differences between the mFC and PRET groups at 12 and 24 months on any
of the cognitive outcomes measured in this study (Table 2).
Change from baseline: The effect in each intervention arm at 12 and 24 months
Author Manuscript
Digit Span Forward and Backwards Sum Score—The mFC and PRET groups
improved their Digit Span scores at 12 (mFC: estimated difference, 0.3; Inter-quartile range,
0, 0.7; p=0.04; PRET: 0.7; 0.3, 1; p<0.01; Table 3 and Figure 1A) and at 24 months (mFC:
0.7; 0.3, 1.7; p<0.01; PRET: 0.5; 0.2, 0.8; p<0.01; Table 3 and Figure 1A).
Stroop Color-Word Interference T-Score—The mFC group improved performance on
the Stroop at 12 months (mFC: 0.3; 0, 0.6; p=0.04; Table 3 and Figure 1B), while the PRET
group presented with no change (0.2; −0.1, 0.8; p=0.08; Table 3 and Figure 1B). At 24
months, the mFC and PRET groups improved their Stroop scores (mFC: 0.3; 0.1, 0.5;
p=0.03; PRET: 0.2; −0.1, 0.6; p=0.048; Table 3 and Figure 1B).
Author Manuscript
Brief Test of Attention Sum Score—At 12 months, the mFC (0.3; −0.3, 1; p=0.07;
Table 3 and Figure 1C) and the PRET (0; −0.3, 0.5; p=0.11; Table 3 and Figure 1C) groups
did not change on the BTA. At 24 months, mFC remained unchanged, while PRET
improved on the BTA (mFC: 0.1; −0.3, 0.8; p=0.50; PRET: 0.3; 0, 0.8; p=0.048; Table 3
and Figure 1C).
Associations of Change in UPDRS-III, Function, and Cognition—There were no
significant relationships between change in the cognitive outcomes and the UPDRS-III.
With respect to the relationships between change in cognitive outcomes and change in
physical function outcomes, only the relationship between the digit span and walking speed
was significant (rho=0.46, p=0.004).
Author Manuscript
In summary, there are 2 findings of importance at the study end-point. First, there are no
differences between mFC and PRET for all cognitive outcomes measured in this study.
Second, PRET and mFC presented with substantial within group improvement in cognitive
performance, i.e., at 24 months, relative to baseline, the PRET group improved on all three
of the cognitive outcomes (Digit Span, Stroop, and BTA) measured in this study, while the
mFC group improved on two of the three cognitive outcomes (Digit Span and Stroop)
measured in this study. These results did not change with LOCF sensitivity analyses
(supplementary Table e-1 and e-2).
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 6
Adverse events
Author Manuscript
Adverse events related to this trial have been previously published.13 Of note, there were no
neurological or cognitive adverse events reported.
DISCUSSION
Author Manuscript
This clinical trial demonstrated that 24 months of exercise, twice a week, may be effective in
improving attention and working memory in non-demented patients with mild-to-moderate
PD when evaluated off medication. Relative to baseline, mFC and PRET improved
performance on the Digit Span and Stroop, while PRET also improved performance on the
BTA. This is the first randomized clinical trial to examine the effects of 24 months of
exercise on cognitive functions in patients with mild-to-moderate PD. The findings from this
clinical trial extend the previously known cognitive benefits of exercise in Alzheimer’s
disease and in normal aging to PD. In addition, improvements in digit span scores were
associated with improvements in walking speed. Given the recently published finding that
physical activity reduces major mobility disability in older adults at risk for disability,27
taken together with our recently published findings that exercise improves motor signs of
PD13 and physical function,15 and our current finding that exercise might improve cognitive
function, the evidence for the benefits of exercise across domains is accumulating.
Author Manuscript
This clinical trial demonstrates the likely beneficial effects of 24 months of structured
exercise on attention and working memory, which are cognitive domains that are frequently
impaired in patients with PD. This is especially important for the Stroop because impaired
performance on the Stroop has been shown to be associated with greater risk of subsequent
dementia in non-demented patients with PD.28,29 Consequently, the finding that structured
exercise might improve Stroop scores might indicate that exercise may reduce the risk of
subsequent dementia in patients with PD. This possibility is clinically relevant because the
cumulative incidence estimates from longitudinal studies indicate that up to 78% of patients
with PD will develop dementia.6
Author Manuscript
PRET was significantly better than mFC at improving motor signs of PD,13 and PRET and
mFC were efficacious at improving physical function15 and cognitive outcomes in PD with
neither being better than the other. One possible explanation is that because the mFC
protocol included non-progressive resistance exercises, it could be considered as a ‘low’
dose resistance exercise regimen, while the PRET protocol could be considered as a ‘high’
dose resistance exercise regimen. It has been shown that both ‘low’ and ‘high’ dose PRET
have similar beneficial effects on cognitive outcomes.30 It could be that there is a threshold
for a treatment effect on cognitive function. Our findings suggest that PRET and mFC
exceeded a threshold for an effect on cognitive function. Further research is needed to
understand the mechanisms by which exercise improves cognition and whether different
doses of exercise and different types of exercise have the same or different effects on
cognition.
In general, repeated administrations of cognitive assessments in healthy individuals are
known to have practice effects, and these practice effects are affected by factors such as age,
task difficulty,31,32 and IQ.31 We recognize that the improvements observed in this study
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 7
Author Manuscript
Author Manuscript
could have been driven by practice effects. However, there are two arguments that favor the
idea that the improvements in cognitive outcomes observed in this study were at least
partially attributable to the effect of exercise and not simply an effect of practice. First,
cognitive function has been shown to decline with increasing age and the magnitude of this
decline is approximated by the improvement in cognitive function due to repeated testing.33
Second, in PD, the neurodegenerative disease process augments the cognitive decline that
accompanies the aging process. In fact, prior work has shown that when cognitive tests are
administered approximately 36 months apart, more cognitive decline occurs in patients with
PD when compared to age-matched controls.34 Consequently, combining the effects of
aging and the neurodegenerative disease process one would expect cognitive function to
decline or at best remain unchanged over time in patients with PD. However, we observed
improvements in performance in the mFC and PRET groups in the cognitive outcomes at 12
and 24 months. This might be suggestive of an effect of exercise beyond that of practice
alone.
Author Manuscript
Another factor that is a potential confound is the increased social and cognitive engagement
by virtue of mere participation in the PRET-PD study. The very fact that these patients went
out of their houses to the gyms provides for greater opportunities for social and cognitive
engagement with others including their family, personal trainers, and the study personnel.
The extent to which this increased social and cognitive engagement confounds our findings
is unknown. This is a limitation of this study. In addition, due to a relatively younger group
of patients, mild-to-moderate disease, and an above average level of education, the lack of
generalizability is a limitation. Given these limitations and the fact that we did not adjust our
α-level for multiple outcomes, our findings should be interpreted with caution. Despite these
limitations, the PRET-PD trial is similar to a phase 2 study that supports the concept of
exercise as an adjunct therapy for PD and demonstrates feasibility,35 thereby providing a
rationale for larger-scale multi-center trials, that could extend our findings across geographic
locations, clinical practices, and a wider group of patients with PD.
In conclusion, this clinical trial found that 24 months of PRET or mFC exercise may
improve cognitive outcomes in mild-to-moderate PD while off medication. Our findings
suggest that non-demented patients with mild-to-moderate PD might be able to improve
cognitive performance by engaging in either mFC or PRET for two 60 to 90 minute sessions
a week.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Author Manuscript
Acknowledgments
Full Financial Disclosures: FJD, JAR, SEL and CP received grant support from NIH. DEV received grant support
from NIH, Michael J. Fox, and consults for projects at UT Southwestern Medical Center and Great Lakes
NeuroTechnologies. WMK receives grant support from the NIH and DoD and consulting fees from the NIH. CLC
is or has received research support from Allergan Inc., Merz Pharmaceuticals, Ipsen Limited, NIH, and Parkinson
Disease Foundation and consulting fees from Neupathe, Allergan Inc., Merz Pharmaceuticals, Ipsen Limited and
Medtronic Corporation. JGG has received grant/research support from NIH, Michael J. Fox Foundation, Rush
University, Teva (site-PI) and consulting fees from Merz Pharmaceuticals and Pfizer. DMC received grant support
from NIH and Michael J. Fox, and receives lecture and reviewer fees from NIH.
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 8
Author Manuscript
Funding Source: Supported by NIH (R01-NS28127-12 to 16, R01 NS52318, R01 NS75012). The sponsors were
not involved in the design, conduct, collection, management, analysis, and/or interpretation of the study results and
preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and
do not necessarily reflect the position or policy of NIH.
REFERENCES
Author Manuscript
Author Manuscript
Author Manuscript
1. Brown RG, Marsden CD. Cognitive function in parkinsons-disease - from description to theory.
Trends Neurosci. 1990; 13(1):21–29. [PubMed: 1688671]
2. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated
parkinsons-disease and its relationship to motor disability. Brain. 1991; 114:2095–2122. [PubMed:
1933236]
3. Owen AM. Cognitive dysfunction in parkinson disease: The role of frontostriatal circuitry.
Neuroscientist. 2004; 10(6):525–537. ER. [PubMed: 15534038]
4. Kudlicka A, Clare L, Hindle JV. Executive functions in parkinson's disease: Systematic review and
meta-analysis. Mov Disord. 2011; 26(13):2305–2315. [doi]. [PubMed: 21971697]
5. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of
parkinsons-disease. Brain. 1992; 115:1727–1751. [PubMed: 1486458]
6. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of
dementia in parkinson disease - an 8-year prospective study. Arch Neurol. 2003; 60(3):387–392.
[PubMed: 12633150]
7. Goldman JG, Litvan I. Mild cognitive impairment in parkinson's disease. Minerva Med. 2011;
102(6):441–459. [PubMed: 22193376]
8. Bullain SS, Corrada MM, Shah BA, Mozaffar FH, Panzenboeck M, Kawas CH. Poor physical
performance and dementia in the oldest old: The 90+ study. JAMA Neurol. 2013; 70(1):107–113.
[doi]. [PubMed: 23090391]
9. Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: A meta-analytic
study. Psychological Science. 2003; 14(2):125–130. [PubMed: 12661673]
10. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with
cognitive impairment and dementia: A meta-analysis. Arch Phys Med Rehabil. 2004; 85(10):
1694–1704. [PubMed: 15468033]
11. Uc EY, Doerschug KC, Magnotta V, et al. Phase I/II randomized trial of aerobic exercise in
parkinson disease in a community setting. Neurology. 2014; 83(5):413–425. [doi]. [PubMed:
24991037]
12. Hindle JV, Petrelli A, Clare L, Kalbe E. Nonpharmacological enhancement of cognitive function in
parkinson's disease: A systematic review. Mov Disord. 2013; 28(8):1034–1049. doi:10.1002/mds.
25377;10.1002/mds.25377. [PubMed: 23426759]
13. Corcos DM, Robichaud JA, David FJ, et al. A two-year randomized controlled trial of progressive
resistance exercise for parkinson's disease. Mov Disord. 2013 doi:10.1002/mds.25380;10.1002/
mds.25380.
14. Cianci, H. Parkinson disease: Fitness counts. 3rd ed.. Miami, FL: National Parkinson Foundation;
2006.
15. Prodoehl J, Rafferty MR, David FJ, et al. Two-year exercise program improves physical function
in parkinson's disease: The PRET-PD randomized clinical trial. Neurorehabil Neural Repair. 2014
[pii].
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical-diagnosis of idiopathic
parkinsons-disease - a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry.
1992; 55(3):181–184. [PubMed: 1564476]
17. Canadian Society for Exercise Physiology. Physical activity readiness questionnaire - PAR -Q
(revised 2002). 2013 http://uwfitness.uwaterloo.ca/PDF/par-q.pdf. Updated 2002.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the
cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189–198. [PubMed:
1202204]
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 9
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
19. Feigenbaum MS, Pollock ML. Prescription of resistance training for health and disease. Med Sci
Sports Exerc. 1999; 31(1):38–45. [PubMed: 9927008]
20. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral
transplantations (capit). Mov Disord. 1992; 7(1):2–13. [PubMed: 1557062]
21. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in
parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex.
2001; 11(12):1136–1143. [PubMed: 11709484]
22. Wechsler, D. Wechsler adult intelligence scale: Administration and scoring Manual <br/>. Third
ed.. San Antonio, TX: Psychological Corporation; 1997.
23. Golden, CJ.; Freshwater, SM. The stroop color and word test: A manual for clinical and
experimental uses. Chicago, IL: Stoelting; 2002.
24. Schretlen, D. Brief test of attention: Professional manual. Lutz, FL: Psychological Assessment
Resources, Inc.; 1997.
25. Fahn, S.; Elton, RL. UPDRS Program Members. Unified parkinson's disease rating scale. In: Fahn,
S.; Marsden, CD.; Goldstein, M.; Calne, DB., editors. Recent developments in parkinsons disease.
Vol. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153-163.
26. Friedman, LM.; Furberg, CD.; DeMets, DL. Fundamentals of clinical trials. New York: SpringerVerlag; 1998.
27. Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention
of major mobility disability in older adults: The LIFE study randomized clinical trial. JAMA.
2014; 311(23):2387–2396. [doi]. [PubMed: 24866862]
28. Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsychological
prediction of dementia in parkinson's disease. J Neurol Neurosurg Psychiatry. 1998; 64(2):178–
183. [PubMed: 9489527]
29. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in parkinson's disease: A
community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol. 2005; 18(3):149–154.
[PubMed: 16100104]
30. Liu-Ambrose T, Nagamatsu LS, Graf P, Beattie BL, Ashe MC, Handy TC. Resistance training and
executive functions A 12-month randomized controlled trial. Arch Intern Med. 2010; 170(2):170–
178. [PubMed: 20101012]
31. Rabbitt, P. Crystal quest: An examination of the concepts of 'fluid' and 'crystallised' intelligence as
explanations for cognitive changes in old age. In: Baddeley, AD.; Weiskrantz, LS., editors.
Attention, selection, awareness and control. Oxford: Oxford University Press; 1993. p. 197-231.
32. Lowe C, Rabbitt P. Test/re-test reliability of the CANTAB and ISPOCD neuropsychological
batteries: Theoretical and practical issues. cambridge neuropsychological test automated battery.
international study of post-operative cognitive dysfunction. Neuropsychologia. 1998; 36(9):915–
923. [PubMed: 9740364]
33. Rabbitt P, Diggle P, Smith D, Holland F, Mc Innes L. Identifying and separating the effects of
practice and of cognitive ageing during a large longitudinal study of elderly community residents.
Neuropsychologia. 2001; 39(5):532–543. [PubMed: 11254936]
34. Muslimovic D, Post B, Speelman JD, De Haan RJ, Schmand B. Cognitive decline in parkinson's
disease: A prospective longitudinal study. J Int Neuropsychol Soc. 2009; 15(3):426–437.
[PubMed: 19402929]
35. Rascol O. Physical exercise in parkinson disease: Moving toward more robust evidence? Mov
Disord. 2013; 28(9):1173–1175. [doi]. [PubMed: 23589379]
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 10
Author Manuscript
Figure 1.
Author Manuscript
These box plots illustrate the off-medication change from baseline z-scores in the modified
Fitness Counts (mFC) and Progressive Resistance Exercise Training (PRET) for (A) the
Digit Span Forwards and Backwards, (B) the Stroop Color-Word Interference, and (C) the
Brief Test of Attention at 12, and 24 months. Positive z-scores indicate improvement in the
Digit Span Forwards and Backwards sum score, the Stroop Color-Word Interference Tscore, and the Brief Test of Attention sum score.
Author Manuscript
Author Manuscript
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 11
Table 1
Author Manuscript
Characteristics of Patients at Baseline1
Treatment groups
mFC
PRET
PRET vs. mFC
(95% CI)
p-value2
Age in years
58·6 ± 5·6
59·0 ± 4·6
−0·4 (−2·6 to 3·4)
0·783
Education in years
15·9 ± 2·7
16·8 ± 3·5
0.9 (−1.0 to 2.7)
0.373
Demographic
14
Sex - no. (%)
Male
14 (58·3)
14 (58·3)
Female
10 (41·7)
10 (41·7)
0.194
Ethnicity - no. (%)
Author Manuscript
Hispanic or Latino
5 (20·8)
1 (4·2)
Not Hispanic or Latino
19 (79·2)
23 (95·8)
0.494
Race - no. (%)
African American
0 (0)
2 (8·3)
Native American
0 (0)
0 (0)
24 (100)
22 (91·7)
White
14
Handedness - no. (%)
Right
Left
22 (91·7)
23 (95·8)
2 (8·3)
1 (4·2)
6·5 ± 47
6·5 ± 4·1
0·0 (−2·5 to 2·6)
0·973
29·1 ± 1·4
29·3 ± 1·1
−0·2 (−0·9 to 0·5)
0·63
0·5 (0·2 to 1·6)
0·374
Clinical
Years since diagnosis
Mini-Mental State Examination
Author Manuscript
Most affected side - no. (%)
Right
17 (70·8)
13 (54·2)
Left
7 (29·2)
11 (45·8)
Unified Parkinson Disease Rating Scale, part III, motor subscale score
(range, 0–108) (off medication)
34·7 ± 11·5
34·5 ± 11·9
−0·2 (−7·0 to 6·6)
0·953
Hoehn and Yahr Staging Scale (disability; range, 0–5; off medication)
2 (2, 2.5)
2 (2, 2.5)
0 (0 to 0)5
0.856
Dopamine Precursors
19 (79)
17 (71)
0.514
Dopamine Agonists
16 (67)
17 (71)
0.764
Adjuncts
12 (50)
10 (42)
0.564
17 (14.5, 19)
17 (15, 19.5)
0 (−2 to 2)5
0.846
Stroop Color-Word Interference T-Score (mean, 50; SD, 10; off medication)
47.5 (41, 53)
41 (33, 51)
−3 (−11 to 4)5
0.416
Brief Test of Attention Sum Score (range, 0–20; off medication)
16 (13, 18.5)
17 (13.5, 18)
0 (−2 to 2)5
0.756
Motor Status
Medication – n (%)
Author Manuscript
Cognitive Outcomes – median (IQR)
Digit Span Forwards and Backwards Sum Score (range, 0–30; off
medication)
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 12
mFC, Modified Fitness Counts; PRET, Progressive Resistance Exercise Training; CI, Confidence Interval; scPD, Standard of Care Parkinson
Disease; IQR, Inter-Quartile Range
1
Plus-minus values are mean ± 1SD
Author Manuscript
2
Representing significance of a test that was performed to determine if values were the same across the mFC and PRET groups
3
P values calculated using t-test
4
P values calculated using Chi-Square test (expected cell count ≥5) or Fisher’s Exact test (expected cell count <5)
5
Hodges-Lehman estimate of location shift
6
P values calculated using Wilcoxon Rank-Sum test
Author Manuscript
Author Manuscript
Author Manuscript
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 13
Table 2
Author Manuscript
Difference between groups in change from baseline in cognitive outcomes at 12 and 24 months
PRET vs. mFC (95% CI)1
Digit Span Forwards and Backwards (z-score)
12 months
−0.3 (−0.7 to 0.3)
p = 0.32
24 months
0.3 (−0.3 to 1)
p = 0.27
Stroop Color-Word Interference (z-score)
12 months
0.1 (−0.5 to 0.5)
p = 0.81
24 months
0 (−0.4 to 0.5)
p = 0.77
Brief Test of Attention (z-score)
Author Manuscript
12 months
0 (−0.5 to 0.5)
p = 0.77
24 months
0 (−0.8 to 0.5)
p = 0.83
PRET, Progressive Resistance Exercise Training; mFC, Modified Fitness Counts; CI, Confidence Interval
1
Hodges-Lehman estimate of location shift and p-values calculated using Wilcoxon Rank-Sum test
Author Manuscript
Author Manuscript
Mov Disord. Author manuscript; available in PMC 2016 October 01.
David et al.
Page 14
Table 3
Author Manuscript
Cognitive outcomes at baseline, 12, and 24 months, and change from baseline at 12 and 24 months
Z-Score at visit: Median (IQR)
mFC
PRET
Change from baseline: Median
(IQR), p value1
mFC
PRET
Digit Span Forwards and Backwards2
Baseline
0 (−0.3, 0.6)
0.3 (−0.3, 0.8)
12 months
0.3 (−0.3, 1.3)
1 (0, 1.7)
0.3 (0, 0.7)
p = 0.04
0.7 (0.3, 1)
p < 0.01
24 months
1 (0, 2)
1 (0.2, 1.3)
0.7 (0.3, 1.7)
p < 0.01
0.5 (0.2, 0.8)
p < 0.01
Baseline
−0.3 (−0.9, 0.3)
−0.9 (−1.7, 0.1)
12 months
−0.1 (−0.8, 0.8)
−0.2 (−1.2, 0.4)
0.3 (0, 0.6)
p = 0.04
0.2 (−0.1, 0.8)
p = 0.08
24 months
−0.1 (−0.8, 0.8)
−0.1 (−1.7, 0.4)
0.3 (0.1, 0.5)
p = 0.03
0.2 (−0.1, 0.6)
p = 0.048
Baseline
0.1 (−0.7, 0.8)
0.4 (−0.5, 0.7)
12 months
0.4 (−0.4, 1.2)
0.4 (−0.4, 0.9)
0.3 (−0.3, 1)
p = 0.07
0 (−0.3, 0.5)
p = 0.11
24 months
−0.1 (−0.4, 0.9)
0.4 (0.1, 1.2)
0.1 (−0.3, 0.8)
p = 0.50
0.3 (0, 0.8)
p = 0.048
Stroop Color-Word Interference2
Author Manuscript
Brief Test of Attention2
IQR, Inter-Quartile Range; mFC, Modified Fitness Counts; PRET, Progressive Resistance Exercise Training
1
P values calculated using the Wilcoxon Signed Rank test
2
Positive change score from baseline is indicative of improvement
Author Manuscript
Author Manuscript
Mov Disord. Author manuscript; available in PMC 2016 October 01.